My career path changed entirely. I became board-certified in obesity medicine in 2020, and I’ve dedicated my work to helping ...

The diet has been linked to weight loss, longer life span and even a lower risk of cancer - in mice. What about humans?

Roche released Phase 2 trial results showing its weekly obesity drug CT-388 helped patients lose up to 22.5% body weight with ...

The woman only wanted to look her best in her bridesmaid dress. She followed an extreme routine and cut out most food items to lose weight.

Roche said the Phase II results help build the case for advancing CT-388 into late-stage testing, which is set to get underway this quarter.

Compare intermittent fasting and keto to learn how each affects weight loss and blood sugar. Find out which eating style ...

BERLIN, Jan 27 (Reuters) - Swiss pharmaceutical firm Roche said on Tuesday that a phase II clinical trial of its experimental ...

A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p ...

Roche’s CT-388 phase 2 obesity results show 22.5% weight loss and solid tolerability vs tirzepatide—plus what’s next for ...

Developed by board-certified endocrinologist Dr. Eiriny Eskander, Caloria delivers physician-backed insights for people managing GLP-1 use, diabetes, PCOS, and menopause.

Custom formulations of popular weight loss medications have surged in popularity due to the high costs of FDA-approved drugs. Here’s what to know about their benefits and risks.

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.